The identification of compound AMD11070 (6) as a potent CXCR4 antagonist shed light on (S)-5,6,7,8-tetrahydroquinolin-8-amine as a privileged scaffold for the development of novel compounds not only as anti-HIV drugs but also agents able to inhibit cancer progression via several mechanisms, as CXCR4 is a chemokine receptor expressed on the surface of many cancer cell types. Here, CXCR4 is linked to cancer.